About PAM²L Biotechnologies
PAM²L Biotechnologies is a company based in China founded in 2021 by Zhong Chao. PAM²L Biotechnologies has raised $14.81 million across 1 funding round from investors including Yunqi Partners, Xinwo Capital Holding Group and CoStone Capital. PAM²L Biotechnologies operates in a competitive market with competitors including AmerisourceBergen, Hybio Pharmaceutical, Dizal Pharma, Quanyuantang Pharmacy and Guiyang Xintian Pharmaceutical, among others.
- Headquarter China
- Founders Zhong Chao
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.81 M (USD)
in 1 rounds
-
Latest Funding Round
$14.81 M (USD), Seed
Jan 11, 2023
-
Investors
Yunqi Partners
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PAM²L Biotechnologies
PAM²L Biotechnologies has successfully raised a total of $14.81M through 1 strategic funding round. The most recent funding activity was a Seed round of $14.81 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PAM²L Biotechnologies
PAM²L Biotechnologies has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Yunqi Partners, Xinwo Capital Holding Group and CoStone Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in tech startups by Yunqi Partners.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for PAML Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PAM²L Biotechnologies
Investment portfolio details for PAML Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PAML Biotechnologies
Detailed financials for PAML Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pam²l Biotechnologies Comparisons
Peer comparison for PAML Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PAM²L Biotechnologies
PAM²L Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmerisourceBergen, Hybio Pharmaceutical, Dizal Pharma, Quanyuantang Pharmacy and Guiyang Xintian Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical distribution and supply chain services are provided globally.
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
Pharmaceutical research and development are focused on oncology therapeutics.
|
|
| Locked | Locked | Locked |
Medical and pharmaceutical products are retailed offline and online.
|
|
| Locked | Locked | Locked |
Pharmaceutical company in China
|
|
| Locked | Locked | Locked |
Pharmaceutical products are sold via an e-commerce platform in China.
|
Detailed competitors of PAML Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pam²l Biotechnologies
Complete news archive for PAML Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PAM²L Biotechnologies
PAM²L Biotechnologies was founded in 2021 and raised its 1st funding round 2 years after it was founded.
PAM²L Biotechnologies is headquartered in China.
PAM²L Biotechnologies is a funded company, having raised a total of $14.81M across 1 funding round to date.
PAML Biotechnologies was founded in 2021 by Zhong Chao in China. Operations are centered on the bio-pharmaceutical sector, where products are supplied and wholesaled to various markets. Distribution activities are managed from the companys base in China, with a focus on wholesale services for pharmaceutical and biotechnological items. The domain pam2l.com supports online presence for these core functions.
PAM²L Biotechnologies's top competitors include AmerisourceBergen, Hybio Pharmaceutical and Dizal Pharma.
PAM²L Biotechnologies has 5 investors. Key investors include Yunqi Partners, Xinwo Capital Holding Group, CoStone Capital, Yael Capital, and Fuhua Group.